Investigational New Drugs

, Volume 31, Issue 5, pp 1283–1293 | Cite as

Effect of small angiokinase inhibitor nintedanib (BIBF 1120) on QT interval in patients with previously untreated, advanced renal cell cancer in an open-label, phase II study

  • Tim EisenEmail author
  • Yaroslav Shparyk
  • Nicholas Macleod
  • Robert Jones
  • Gudrun Wallenstein
  • Graham Temple
  • Yasser Khder
  • Claudia Dallinger
  • Matus Studeny
  • Arsene-Bienvenu Loembe
  • Igor Bondarenko


Purpose Some targeted anticancer agents are associated with serious ventricular tachyarrhythmias, which may be predicted by electrocardiographic evaluation of drug-related QT prolongation. We studied the effects of nintedanib (BIBF 1120; an oral, triple angiokinase inhibitor targeting vascular endothelial growth factor, fibroblast growth factor, and platelet-derived growth factor receptors) on the QT interval in patients with renal cell carcinoma (RCC) participating in an open-label phase II trial. Methods Treatment-naïve, adult patients with unresectable/metastatic, clear cell RCC received nintedanib 200 mg twice daily. QT intervals were evaluated at baseline (day −1), on day 1 (after the first dose), and on day 15 (steady state) by 12-lead electrocardiograms (ECGs) performed in triplicate. Pharmacokinetic sampling was also undertaken. Results Among 64 evaluable patients, the upper limits of the 2-sided 90 % confidence intervals for the adjusted mean time-matched changes in QTcF interval (corrected for heart rate by Fridericia’s method) from baseline to day 1 and 15 (primary ECG endpoint) were well below the regulatory threshold of 10 ms at all times. No relationship between nintedanib exposure and change from baseline in QTcF was seen. Nintedanib was generally well tolerated with no drug-related cardiovascular adverse events. Conclusion Nintedanib administered at 200 mg twice daily was not associated with clinically relevant QT prolongation.


Nintedanib BIBF 1120 Renal cell carcinoma RCC QT interval Phase II Angiogenesis inhibitor 



The trial was sponsored by Boehringer Ingelheim Ltd, Bracknell, UK. The authors were fully responsible for all content and editorial decisions, were involved at all stages of manuscript development, and have approved the final version. Medical writing assistance, supported financially by Boehringer Ingelheim, was provided by Duncan Campbell of GeoMed during the preparation of this manuscript.

Conflicts of interest

Tim Eisen has participated in advisory boards and given talks for Boehringer Ingelheim for which he has received honoraria. Yaroslav Shparyk has received research funding from Boehringer Ingelheim. Nicholas Macleod has received research funding from Boehringer Ingelheim. Robert Jones has received research funding from Boehringer Ingelheim. Gudrun Wallenstein is an employee of Boehringer Ingelheim. Graham Temple is an employee of Boehringer Ingelheim. Yasser Khder is an employee of Boehringer Ingelheim. Claudia Dallinger is an employee of Boehringer Ingelheim. Matus Studeny is an employee of Boehringer Ingelheim. Arsene-Bienvenu Loembe is an employee of Boehringer Ingelheim. Igor Bondarenko has received research funding from Boehringer Ingelheim

Financial support

The trial was sponsored by Boehringer Ingelheim Ltd, Bracknell, UK.

Supplementary material

10637_2013_9962_MOESM1_ESM.doc (276 kb)
ESM 1 (DOC 276 kb)


  1. 1.
    Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335–2342CrossRefGoogle Scholar
  2. 2.
    Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355:2542–2550CrossRefGoogle Scholar
  3. 3.
    Bergers G, Hanahan D (2008) Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 8:592–603CrossRefGoogle Scholar
  4. 4.
    Folkman J (2006) Antiangiogenesis in cancer therapy–endostatin and its mechanisms of action. Exp Cell Res 312:594–607CrossRefGoogle Scholar
  5. 5.
    Hilberg F, Roth GJ, Krssak M, Kautschitsch S, Sommergruber W, Tontsch-Grunt U, Garin-Chesa P, Bader G, Zoephel A, Quant J, Heckel A, Rettig WJ (2008) BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res 68:4774–4782CrossRefGoogle Scholar
  6. 6.
    Bousquet G, Alexandre J, Le TC, Goldwasser F, Faivre S, de Mont-Serrat H, Kaiser R, Misset JL, Raymond E (2011) Phase I study of BIBF 1120 with docetaxel and prednisone in metastatic chemo-naive hormone-refractory prostate cancer patients. Br J Cancer 105:1640–1645CrossRefGoogle Scholar
  7. 7.
    Mross K, Stefanic M, Gmehling D, Frost A, Baas F, Unger C, Strecker R, Henning J, Gaschler-Markefski B, Stopfer P, de Rossi L, Kaiser R (2010) Phase I study of the angiogenesis inhibitor BIBF 1120 in patients with advanced solid tumors. Clin Cancer Res 16:311–319CrossRefGoogle Scholar
  8. 8.
    Reck M, Kaiser R, Eschbach C, Stefanic M, Love J, Gatzemeier U, Stopfer P, von Pawel J (2011) A phase II double-blind study to investigate efficacy and safety of two doses of the triple angiokinase inhibitor BIBF 1120 in patients with relapsed advanced non-small-cell lung cancer. Ann Oncol 22:1374–1381CrossRefGoogle Scholar
  9. 9.
    Ledermann JA, Hackshaw A, Kaye S, Jayson G, Gabra H, McNeish I, Earl H, Perren T, Gore M, Persic M, Adams M, James L, Temple G, Merger M, Rustin G (2011) Randomized phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancer. J Clin Oncol 29:3798–3804CrossRefGoogle Scholar
  10. 10.
    Haverkamp W, Breithardt G, Camm AJ, Janse MJ, Rosen MR, Antzelevitch C, Escande D, Franz M, Malik M, Moss A, Shah R (2000) The potential for QT prolongation and pro-arrhythmia by non-anti-arrhythmic drugs: clinical and regulatory implications. Report on a Policy Conference of the European Society of Cardiology. Cardiovasc Res 47:219–233CrossRefGoogle Scholar
  11. 11.
    Lasser KE, Allen PD, Woolhandler SJ, Himmelstein DU, Wolfe SM, Bor DH (2002) Timing of new black box warnings and withdrawals for prescription medications. JAMA 287:2215–2220CrossRefGoogle Scholar
  12. 12.
    ICH Steering Committee (2012) The clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs, in Guideline IHT.
  13. 13.
    Health Canada (2010) Guide for the analysis and review of QT/QTc interval data.
  14. 14.
    Liu Q, Madabushi R, Garnett C, Booth B (2008) Experience in QT evaluation of oncology drug products since ICH E14 guidance. J Clin Oncol 26(suppl):abstr 2554CrossRefGoogle Scholar
  15. 15.
    CAPRELSA® (vandetanib) tablets (2011) Full prescribing information. Accessed 4 October 2012
  16. 16.
    Tasigna® (nilotinib) capsules (2012) Full prescribing information. Accessed 4 October 2012
  17. 17.
    VOTRIENT® (pazopanib) tablets (2012) Full prescribing information. Accessed 4 October 2012
  18. 18.
    TYKERB (lapatinib) tablets (2012) Full prescribing information. Accessed 4 October 2012
  19. 19.
    Bello CL, Mulay M, Huang X, Patyna S, Dinolfo M, Levine S, Van VA, Toh M, Baum C, Rosen L (2009) Electrocardiographic characterization of the QTc interval in patients with advanced solid tumors: pharmacokinetic- pharmacodynamic evaluation of sunitinib. Clin Cancer Res 15:7045–7052CrossRefGoogle Scholar
  20. 20.
    Tolcher AW, Appleman LJ, Shapiro GI, Mita AC, Cihon F, Mazzu A, Sundaresan PR (2011) A phase I open-label study evaluating the cardiovascular safety of sorafenib in patients with advanced cancer. Cancer Chemother Pharmacol 67:751–764CrossRefGoogle Scholar
  21. 21.
    Sereno M, Brunello A, Chiappori A, Barriuso J, Casado E, Belda C, de Castro J, Feliu J, Gonzalez-Baron M (2008) Cardiac toxicity: old and new issues in anti-cancer drugs. Clin Transl Oncol 10:35–46CrossRefGoogle Scholar
  22. 22.
    Brell JM (2010) Prolonged QTc interval in cancer therapeutic drug development: defining arrhythmic risk in malignancy. Prog Cardiovasc Dis 53:164–172CrossRefGoogle Scholar
  23. 23.
    Finkle J, Bloomfield D, Uhl K, Sanhai W, Stockbridge N, Krucoff MW (2009) New precompetitive paradigms: focus on cardiac safety. Am Heart J 157:825–826CrossRefGoogle Scholar
  24. 24.
    Morganroth J, Shah RR, Scott JW (2010) Evaluation and management of cardiac safety using the electrocardiogram in oncology clinical trials: focus on cardiac repolarization (QTc interval). Clin Pharmacol Ther 87:166–174CrossRefGoogle Scholar
  25. 25.
    Rock EP, Finkle J, Fingert HJ, Booth BP, Garnett CE, Grant S, Justice RL, Kovacs RJ, Kowey PR, Rodriguez I, Sanhai WR, Strnadova C, Targum SL, Tsong Y, Uhl K, Stockbridge N (2009) Assessing proarrhythmic potential of drugs when optimal studies are infeasible. Am Heart J 157:827–36.e1CrossRefGoogle Scholar
  26. 26.
    Frederica LS (1920) Dir Systolendauer in Elektrokardiogramm bei normalen Menschen und bei Herzkranken. Acta Med Scand 469–486Google Scholar
  27. 27.
    Okamoto I, Kaneda H, Satoh T, Okamoto W, Miyazaki M, Morinaga R, Ueda S, Terashima M, Tsuya A, Sarashina A, Konishi K, Arao T, Nishio K, Kaiser R, Nakagawa K (2010) Phase I safety, pharmacokinetic, and biomarker study of BIBF 1120, an oral triple tyrosine kinase inhibitor in patients with advanced solid tumors. Mol Cancer Ther 9:2825–2833CrossRefGoogle Scholar
  28. 28.
    Bazett HC (1920) An analysis of the time-relations of electrocardiograms. Heart 353–370Google Scholar
  29. 29.
    Schmidinger M, Zielinski CC, Vogl UM, Bojic A, Bojic M, Schukro C, Ruhsam M, Hejna M, Schmidinger H (2008) Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 26:5204–5212CrossRefGoogle Scholar
  30. 30.
    Chu TF, Rupnick MA, Kerkela R, Dallabrida SM, Zurakowski D, Nguyen L, Woulfe K, Pravda E, Cassiola F, Desai J, George S, Morgan JA, Harris DM, Ismail NS, Chen JH, Schoen FJ, Van den Abbeele AD, Demetri GD, Force T, Chen MH (2007) Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 370:2011–2019CrossRefGoogle Scholar
  31. 31.
    Di Lorenzo G, Utorino R, Runi G, Arteni G, Icevuto E, Udini M, Icorella C, Omano C, Ieta M, Iordano A, Iuliano M, Onnella A, de Nunzio C, Izzo M, Ontesarchio V, Wer M, de Placido S (2009) Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: a multicenter analysis. Ann Oncol 20:1535–1542CrossRefGoogle Scholar
  32. 32.
    Mego M, Reckova M, Obertova J, Sycova-Mila Z, Brozmanova K, Mardiak J (2007) Increased cardiotoxicity of sorafenib in sunitinib-pretreated patients with metastatic renal cell carcinoma. Ann Oncol 18:1906–1907CrossRefGoogle Scholar
  33. 33.
    Telli ML, Witteles RM, Fisher GA, Srinivas S (2008) Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate. Ann Oncol 19:1613–1618CrossRefGoogle Scholar
  34. 34.
    INLYTA® (axitinib) tablets for oral administration (2012) Full prescribing information. Accessed 4 October 2012
  35. 35.
    Kropff M, Kienast J, Bisping G, Berdel WE, Gaschler-Markefski B, Stopfer P, Stefanic M, Munzert G (2009) An open-label dose-escalation study of BIBF 1120 in patients with relapsed or refractory multiple myeloma. Anticancer Res 29:4233–4238PubMedGoogle Scholar
  36. 36.
    Stopfer P, Rathgen K, Bischoff D, Ludtke S, Marzin K, Kaiser K, Wagner K, Ebner T (2011) Pharmacokinetics and metabolism of BIBF 1120 after oral dosing to healthy male volunteers. Xenobiotica 41:297–311CrossRefGoogle Scholar
  37. 37.
    Ellis PM, Kaiser R, Zhao Y, Stopfer P, Gyorffy S, Hanna N (2010) Phase I open-label study of continuous treatment with BIBF 1120, a triple kinase inhibitor, and pemetrexed in pretreated non-small cell lung cancer patients. Clin Cancer Res 16:2881–2889CrossRefGoogle Scholar
  38. 38.
    du Bois A, Huober J, Stopfer P, Pfisterer J, Wimberger P, Loibl S, Reichardt VL, Harter P (2010) A phase I open-label dose-escalation study of oral BIBF 1120 combined with standard paclitaxel and carboplatin in patients with advanced gynecological malignancies. Ann Oncol 21:370–375CrossRefGoogle Scholar
  39. 39.
    Sarapa N, Huang X, Varterasian M, Fingert H et al (2005) Risk management and eligibility criteria for QTc assessment in patients with advanced cancer (Abstract). J Clin Oncol 23(suppl):abstr 3047CrossRefGoogle Scholar
  40. 40.
    Varterasian M, Meyer M, Fingert H, Radlowski D, Asbury P, Zhou X, Healey D (2003) Baseline heart rate-corrected QT and eligibility for clinical trials in oncology. J Clin Oncol 21:3378–3379CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • Tim Eisen
    • 1
    Email author
  • Yaroslav Shparyk
    • 2
  • Nicholas Macleod
    • 3
  • Robert Jones
    • 3
  • Gudrun Wallenstein
    • 4
  • Graham Temple
    • 5
  • Yasser Khder
    • 6
  • Claudia Dallinger
    • 7
  • Matus Studeny
    • 8
  • Arsene-Bienvenu Loembe
    • 8
  • Igor Bondarenko
    • 9
  1. 1.Cambridge University Health PartnersAddenbrooke’s HospitalCambridgeUK
  2. 2.Lviv State Oncology Regional Treatment and Diagnostic CentreLvivUkraine
  3. 3.CRUK Clinical Research Unit (CRU)GlasgowUK
  4. 4.Boehringer Ingelheim Pharma GmbH & Co. KGIngelheimGermany
  5. 5.Boehringer Ingelheim Ltd.BracknellUK
  6. 6.Boehringer Ingelheim France S.A.S.ReimsFrance
  7. 7.Boehringer Ingelheim Pharma GmbH & Co. KGBiberachGermany
  8. 8.Boehringer Ingelheim RCV GmbH & Co. KGViennaAustria
  9. 9.Dnipropetrovsk State Medical AcademyDnipropetrovskUkraine

Personalised recommendations